Literature DB >> 9835540

Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.

Y S Kim1, Q Liu, L L Chow, H F Chambers, M G Täuber.   

Abstract

The new fluoroquinolone trovafloxacin was tested against a ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus strain in the rabbit model of endocarditis. Trovafloxacin was more effective than vancomycin (CFU/g of vegetation, 2.65 +/- 1.87 versus 4.54 +/- 2.80 [mean +/- standard deviation]; P < 0.05) or ampicillin-sulbactam plus rifampin (4.9 +/- 1.1 CFU/g). The addition of ampicillin-sulbactam to trovafloxacin tended to reduce titers further.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9835540      PMCID： PMC106048     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci.

Authors:  A L Bisno; W E Dismukes; D T Durack; E L Kaplan; A W Karchmer; D Kaye; S H Rahimtoola; M A Sande; J P Sanford; C Watanakunakorn
Journal:  JAMA       Date:  1989-03-10       Impact factor: 56.272

Review 2.  Methicillin-resistant Staphylococcus aureus.

Authors:  W Brumfitt; J Hamilton-Miller
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

3.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Authors:  H F Chambers; S Kennedy
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats.

Authors:  L Cantoni; A Wenger; M P Glauser; J Bille
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

5.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Increasing frequency of staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988.

Authors:  T J Sanabria; J S Alpert; R Goldberg; L A Pape; S H Cheeseman
Journal:  Arch Intern Med       Date:  1990-06

Review 8.  Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections.

Authors:  W E Sanders
Journal:  Rev Infect Dis       Date:  1988 May-Jun

9.  Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus.

Authors:  B J Hartman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus.

Authors:  M Franciolli; J Bille; M P Glauser; P Moreillon
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226
View more
  4 in total

1.  In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.

Authors:  H W Boucher; C Thauvin-Eliopoulos; D Loebenberg; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Trials of the Use of Antimicrobial Agents in Cardiovascular Diseases.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

3.  Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.

Authors:  M Backo; E Gaenger; A Burkart; Y L Chai; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.